pindolol has been researched along with Depression in 21 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
Excerpt | Relevance | Reference |
---|---|---|
"A case is reported of a 34-year-old lady with a 2-year history of resistant depression who responded to pindolol augmentation of sertraline." | 7.70 | Pindolol augmentation of sertraline in resistant depression and its effect on sleep. ( Bell, C; Nutt, DJ; Wilson, S, 1998) |
" After a 1-week placebo run-in period, 72 patients received fluvoxamine 300 mg/day in combination with placebo or pindolol 7." | 6.69 | Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. ( Franchini, L; Gasperini, M; Lucca, A; Perez, J; Smeraldi, E; Zanardi, R, 1998) |
"Of 132 eligible patients with major depression, 111 were randomly assigned to treatment with fluoxetine (20 mg daily) and either placebo or pindolol (7." | 5.08 | Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. ( Alvarez, E; Artigas, F; Faries, D; Gilaberte, I; Pérez, V, 1997) |
"The effect of inositol as an antidepressant was previously demonstrated in both animal models of depression-like behavior and in clinical trials." | 3.71 | The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. ( Belmaker, RH; Bourin, M; Clenet, F; Einat, H; Shaldubina, A, 2001) |
"A case is reported of a 34-year-old lady with a 2-year history of resistant depression who responded to pindolol augmentation of sertraline." | 3.70 | Pindolol augmentation of sertraline in resistant depression and its effect on sleep. ( Bell, C; Nutt, DJ; Wilson, S, 1998) |
"Pindolol was initially used due to its ability to block 5-HT1A receptor-mediated responses and to enhance the neurochemical effects of SSRIs." | 2.43 | Pindolol augmentation of antidepressant response. ( Adell, A; Artigas, F; Celada, P, 2006) |
" In patients who have experienced only partial treatment results, the clinician should first consider optimizing antidepressant dosage or lengthening therapy." | 2.40 | Practical management of treatment-resistant depression. ( Cadieux, RJ, 1998) |
" Using drugs together may increase the risk of adverse effects, through potentiation of existing adverse effects or alterations in plasma concentrations of the drug." | 2.40 | Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. ( Schweitzer, I; Tuckwell, V, 1998) |
" However, the optimal dosing schedule of pindolol remains controversial." | 1.33 | A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. ( Dauphin, A; Gruwez, B; Tod, M, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (4.76) | 18.7374 |
1990's | 11 (52.38) | 18.2507 |
2000's | 7 (33.33) | 29.6817 |
2010's | 2 (9.52) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Laver, B | 1 |
Diwan, M | 1 |
Nobrega, JN | 1 |
Hamani, C | 1 |
Nautiyal, KM | 1 |
Tritschler, L | 1 |
Ahmari, SE | 1 |
David, DJ | 1 |
Gardier, AM | 1 |
Hen, R | 1 |
Jiang, XZ | 1 |
Li, YF | 1 |
Zhang, YZ | 1 |
Chen, HX | 1 |
Li, J | 1 |
Wang, NP | 1 |
Portella, MJ | 1 |
de Diego-Adeliño, J | 1 |
Puigdemont, D | 1 |
Pérez-Egea, R | 1 |
Alvarez, E | 2 |
Artigas, F | 3 |
Pérez, V | 2 |
Gruwez, B | 1 |
Dauphin, A | 1 |
Tod, M | 1 |
Adell, A | 1 |
Celada, P | 1 |
Geretsegger, C | 1 |
Bitterlich, W | 1 |
Stelzig, R | 1 |
Stuppaeck, C | 1 |
Bondy, B | 1 |
Aichhorn, W | 1 |
Tejani-Butt, SM | 1 |
Paré, WP | 1 |
Yang, J | 1 |
Blier, P | 1 |
Bergeron, R | 1 |
Gilaberte, I | 1 |
Faries, D | 1 |
Bourin, M | 2 |
Redrobe, JP | 1 |
Baker, GB | 1 |
Bell, C | 1 |
Wilson, S | 1 |
Nutt, DJ | 1 |
Gurguis, GN | 1 |
Yonkers, KA | 1 |
Blakeley, JE | 1 |
Phan, SP | 1 |
Williams, A | 1 |
Rush, AJ | 1 |
Cryan, JF | 1 |
McGrath, C | 1 |
Leonard, BE | 1 |
Norman, TR | 1 |
Mundo, E | 1 |
Guglielmo, E | 1 |
Bellodi, L | 1 |
Cadieux, RJ | 1 |
Zanardi, R | 1 |
Franchini, L | 1 |
Gasperini, M | 1 |
Lucca, A | 1 |
Smeraldi, E | 1 |
Perez, J | 1 |
Schweitzer, I | 1 |
Tuckwell, V | 1 |
Einat, H | 1 |
Clenet, F | 1 |
Shaldubina, A | 1 |
Belmaker, RH | 1 |
Kohn, R | 1 |
Koella, WP | 1 |
5 reviews available for pindolol and Depression
Article | Year |
---|---|
Pindolol augmentation of antidepressant response.
Topics: Brain; Depression; Humans; Pindolol; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Tr | 2006 |
Practical management of treatment-resistant depression.
Topics: Antidepressive Agents; Buspirone; Depression; Drug Resistance; Drug Therapy, Combination; Humans; Li | 1998 |
Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Drug Resistance; Drug Therapy, | 1998 |
Beta-blockers an important cause of depression: a medical myth without evidence.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents; Antihypertensive Agents; Controlled Clinical Tri | 2001 |
CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action.
Topics: Adrenergic beta-Antagonists; Amphetamine; Animals; Anxiety; Blood-Brain Barrier; Central Nervous Sys | 1985 |
5 trials available for pindolol and Depression
Article | Year |
---|---|
Pindolol augmentation enhances response outcomes in first depressive episodes.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Double-Blind Method; Drug Therapy, Combination | 2009 |
Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients.
Topics: Adult; Depression; Double-Blind Method; Drug Evaluation; Drug Synergism; Female; Humans; Inpatients; | 2008 |
Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 1997 |
Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 1998 |
Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; | 1998 |
11 other studies available for pindolol and Depression
Article | Year |
---|---|
Augmentative therapies do not potentiate the antidepressant-like effects of deep brain stimulation in rats.
Topics: Animals; Behavior, Animal; Buspirone; Deep Brain Stimulation; Depression; Dopamine Antagonists; Gyru | 2014 |
A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors.
Topics: Animals; Animals, Newborn; Anxiety; Autoreceptors; Depression; Disease Models, Animal; Exploratory B | 2016 |
[5-HT1A/1B receptors, alpha2-adrenoceptors and the post-receptor adenylate cyclase activation in the mice brain are involved in the antidepressant-like action of agmatine].
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Agmatine; Animals; Ant | 2008 |
A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.
Topics: Algorithms; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depression; Dose-Res | 2005 |
Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Body Weight; Brain; Carrier Prot | 1994 |
Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings.
Topics: Adrenergic beta-Antagonists; Adult; Buspirone; Depression; Drug Resistance; Drug Therapy, Combinatio | 1996 |
Pindolol does not act only on 5-HT1A receptors in augmenting antidepressant activity in the mouse forced swimming test.
Topics: Adrenergic beta-Antagonists; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, | 1998 |
Pindolol augmentation of sertraline in resistant depression and its effect on sleep.
Topics: 1-Naphthylamine; Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Brain; Depression; Drug | 1998 |
Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity.
Topics: Adult; Anxiety; Case-Control Studies; Depression; Female; Follicular Phase; GTP-Binding Proteins; Hu | 1998 |
Combining pindolol and paroxetine in an animal model of chronic antidepressant action--can early onset of action be detected?
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic beta-Antagonists; Animals; Antidepressive Agents; | 1998 |
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors.
Topics: Animals; Antidepressive Agents; Benzylamines; Depression; Disease Models, Animal; Drug Interactions; | 2001 |